Genomic Health

Genomic Health is a leading provider of genomic-based diagnostic tests, traded on the NASDAQ under the symbol GHDX. The company tackles the issue of overtreatment in cancer care by leveraging its Oncotype IQ® Genomic Intelligence Platform. This platform enables the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey. With more than 750,000 patients tested in over 90 countries, Genomic Health has become a key player in personalized medicine, especially in breast, colon, and prostate cancer. The company, founded in 2000, is based in Redwood City, California, with international headquarters in Geneva, Switzerland.

Genomic Health's flagship product, the Oncotype DX® portfolio, is a series of genomic tests applied to breast, colon, and prostate cancer. These tests provide valuable insights into the unique biology of a tumor, aiding in optimized treatment decisions. The Oncotype DX tests have redefined personalized medicine and have shown to predict chemotherapy benefit, recurrence in breast cancer, disease aggressiveness, and future risk of prostate cancer. The company is also expanding its test portfolio to include additional liquid- and tissue-based tests through products like the Oncotype SEQ® Liquid Select™ test.

For investors seeking opportunities in the biotechnology, healthcare, and pharmaceutical industries, Genomic Health presents a compelling case. Its track record, international presence, and continued innovation in genomic-based diagnostics contribute to its position as a significant player in the precision medicine space. With a strong focus on addressing healthcare challenges related to cancer treatment, Genomic Health has potential for further growth and impact in the future.